Effects of Descurainia sophia on Oxidative Stress Markers and Thirst Alleviation in Hemodialysis Patients: A Randomized Double-Blinded Placebo-Controlled Cross-Over Clinical Trial
Table 5
The comparison of mean changes in outcome between groups.
Group I (DS administration followed by placebo) vs. Group II (placebo followed by DS administration)
Study groups
DS-placebo
Placebo-DS
value
Thirst score
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−2.4 ± 0.87
−1.9 ± 0.69
0.023
Potassium (mEq/L)
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−0.02 ± 0.89
−0.80 ± 1.73
0.001
Cholesterol (mg/dl)
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−31.00 ± 57.05
−27.48 ± 61.46
0.697
Calcium (mg/dl)
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
0.69 ± 2.06
4.03 ± 4.16
<0.001
Triglycerides (mg/dl)
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−77.09 ± 121.52
−69.17 ± 119.32
0.671
Na
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−2.53 ± 6.96
57.17 ± 67.92
<0.001
OXLDL
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
−531.97 ± 796.47
−267.39 ± 901.84
0.040
ANT
Average (diff DS-diff placebo) vs. average (diff placebo-diff DS)
0.10 ± 0.91
0.24 ± 0.67
0.287
Values are expressed as means ± SD; the drug-placebo group took the drug at first, while the placebo-DS group received a placebo following DS. The independent t-test was used to compare the mean change between study groups. DS, Descurainia sophia.
